A systematic review of antibiotic drug shortages and the strategies employed for managing these shortages.

BACKGROUND

There is a need to examine the impact of increasingly prevalent antibiotic shortages on patient outcomes and on the emergence and spread of antimicrobial resistance (AMR).

OBJECTIVES

To: 1) assess patterns and causes of shortages, 2) investigate the effect of shortages on health systems and patient outcomes, and 3) identify strategies for forecasting and managing shortages.

DATA SOURCES

PubMed/MEDLINE, EMBASE, Scopus, and Web of Science.

STUDY ELIGIBILITY CRITERIA

Studies published in English during January 2000-July 2023.

PARTICIPANTS

Healthcare, policy and strategic teams managing and responding to shortages. Patient populations (adult and children) affected by shortages.

INTERVENTIONS

Strategies, policies, and mitigation options for managing and responding to antibiotic drug shortages.

RISK OF BIAS

Methodological quality of included studies was reviewed using the most appropriate tool from Joanna Briggs Institute critical appraisal tool for each study design.

METHODS

Data synthesis was qualitative and quantitative using descriptive statistics.

RESULTS

The final analysis included 74 studies (61/74, 82.4% high-income countries). Shortages were most reported for piperacillin-tazobactam (21/74, 28.4%) with most of the reported antibiotics being in the WHO Watch category (27/54, 51%). Frequent cause of shortages was disruption in manufacturing including supply of active pharmaceutical ingredient and raw materials. Clinical implications of shortages included increased length of hospital stay, treatment failure after using inferior alternative agents and negative impact on antimicrobial stewardship programmes (AMS). Robust economic impact analysis of shortages is unavailable. Successfully reported mitigation strategies were driven by AMS and infectious diseases teams in hospitals.

CONCLUSIONS

Antibiotic shortages are directly or indirectly driven by economic viability and reliance on single source ingredients. The limited data on clinical outcomes indicates mixed effect with some infections becoming more difficult to treat, though there is no robust data on the impact of shortages on AMR. The mitigation strategies to manage shortages rely heavily on AMS teams.

Informations de copyright

Copyright © 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.